肿瘤细胞治疗研究
英文原题：Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma.
Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma.
头颈部鳞状细胞癌（HNSCC）具有高发病率和死亡率，研究HNSCC的发病机制和潜在治疗策略是取得进一步进展所必需的。
头颈部鳞状细胞癌（HNSCC）具有较高的发病率和死亡率，研究HNSCC的发病机制和潜在治疗策略是取得进一步进展所必需的。免疫治疗是HNSCC的一种重要治疗策略，因为它具有产生广泛且持久抗肿瘤反应的潜力。然而，免疫逃逸限制了免疫治疗的疗效，其机制包括细胞因子失调、免疫检查点扰动以及抑制性细胞群的募集。目前，针对HNSCC的多种免疫治疗策略已被开发，包括免疫检查点抑制剂、共刺激激动剂、抗原疫苗、溶瘤病毒治疗、过继性T细胞转移（ACT）以及表皮生长因子受体（EGFR）靶向治疗。每种策略都有其独特优势，在HNSCC治疗中适当应用这些免疫疗法对患者具有重要价值。因此，本综述全面总结了HNSCC中免疫逃逸的机制以及不同免疫治疗策略的特点，为HNSCC的临床治疗提供基础和思考。
Head and neck squamous cell carcinoma (HNSCC) have a high incidence and mortality rate, and investigating the pathogenesis and potential therapeutic strategies of HNSCC is required for further progress. Immunotherapy is a considerable therapeutic strategy for HNSCC due to its potential to produce a broad and long-lasting antitumor response. However, immune escape, which involves mechanisms including dyregulation of cytokines, perturbation of immune checkpoints, and recruitment of inhibitory cell populations, limit the efficacy of immunotherapy. Currently, multiple immunotherapy strategies for HNSCC have been exploited, including immune checkpoint inhibitors, costimulatory agonists, antigenic vaccines, oncolytic virus therapy, adoptive T cell transfer (ACT), and epidermal growth factor receptor (EGFR)-targeted therapy. Each of these strategies has unique advantages, and the appropriate application of these immunotherapies in HNSCC treatment has significant value for patients. Therefore, this review comprehensively summarizes the mechanisms of immune escape and the characteristics of different immunotherapy strategies in HNSCC to provide a foundation and consideration for the clinical treatment of HNSCC.
MEMBER ACCOUNT
登录成功会直接打开下一页。
